Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway
Open accessAbstract
Objectives: This study aims to explore the effect of bone marrow mesenchymal stem cells (BMSCs) on multiple myeloma (MM) development and the underlying mechanism.Materials and Methods: BMSCs from C57BL/6 J mice were isolated and the third passage was used for subsequent experiments. Additionally, a series of in vitro transwell coculture assays were performed to explore the effects of BMSCs on the proliferation of MM cells 5TGM1 and CD4+ T cells. Furthermore, a 5TGM1-induced MM mice model was established. Moreover, PD-L1 shRNA was transfected into BMSCs to investigate whether PD-1/PD-L1 pathway involved in BMSCs-mediated regulation of T cells and MM growth.Results: Data revealed that BMSCs significantly promoted 5TGM1 proliferation in a dose-dependent manner. Furthermore, BMSCs administration exerted stimulatory effects on MM development in terms of shortening the mouse survival rate, promoting tumor growth, and enhancing inflammatory infiltration in the MM model mice. Moreover, BMSCs decreased the percentage of Th1 and Th17 cells, whereas increased that of Th2 and Treg cells. Their corresponding cytokines of these T cell subsets showed similar alteration in the presence of BMSCs. Additionally, BMSCs significantly suppressed CD4+ T cell proliferation. We also found that PD-L1 shRNA inhibited 5TGM1 proliferation likely through activation of CD4+ T cells. Further in vivo experiments confirmed that PD-L1 inhibition attenuated BMSCs-induced MM growth, inflammation infiltration and imbalance of Th1/Th2 and Th17/Treg.Conclusion: In summary, our findings demonstrated that BMSCs promoted cell proliferation of MM through inhibiting T cell immune responses via PD-1/PD-L1 pathway.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Chen et al.'s study showed that BMSCs increased MM cell proliferation by PD-1/PD-L1 pathway-mediated T cell immune response inhibition.
“in addition, Chen et al.‘s study, which examined how BMSCs affected the development of MM, showed that BMSCs increased MM cell proliferation by PD-1/PD-L1 pathway-mediated T cell immune response inhibition [202].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [202]
Cites
Zheng, W.-P., & Flavell, R. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80240-8 · Cited by 2,384 · see citing works
IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis
Komiyama, Y., Nakae, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S., Sudo, K., & Iwakura, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.566 · Cited by 1,536 · see citing works
Klopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562 · see citing works
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404621 · Cited by 328 · see citing works
Chinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301828 · Cited by 266 · see citing works
Mesenchymal Stromal Cells Promote Tumor Growth through the Enhancement of Neovascularization
Suzuki, K., Sun, R., Origuchi, M., Kanehira, M., Takahata, T., Itoh, J., Umezawa, A., Kijima, H., Fukuda, S., & Saijo, Y. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00157 · Cited by 244 · see citing works
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
Paiva, B., Azpilikueta, A., Puig, N., Ocio, E. M., Sharma, R., Oyajobi, B. O., Labiano, S., San-Segundo, L., Rodriguez, A., Aires-Mejia, I., et al. (2015) · Leukemia · doi:10.1038/leu.2015.79 · Cited by 192 · see citing works
Garayoa, M., Garcia, J. L., Santamaria, C., Garcia-Gomez, A., Blanco, J. F., Pandiella, A., Hernández, J. M., Sanchez-Guijo, F. M., del Cañizo, M.-C., Gutiérrez, N. C., et al. (2009) · Leukemia · doi:10.1038/leu.2009.65 · Cited by 148 · see citing works
Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway
Atsuta, I., Liu, S., Miura, Y., Akiyama, K., Chen, C., An, Y., Shi, S., & Chen, F.-M. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt322 · Cited by 57 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Liu, Z., Mi, F., Han, M., Tian, M., Deng, L., Meng, N., Luo, J., & Fu, R. (2021) · Clinical and Experimental Immunology · doi:10.1111/cei.13594 · Cited by 29 · see citing works
Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27 · see citing works
“…strategy for myeloma by reducing CD8 + T cell immunological response [200, 201]. in addition, Chen et al.‘s study, which examined how BMSCs affected the development of MM, showed that BMSCs increased MM cell proliferation by PD-1/PD-L1 pathway-mediated T cell immune response inhibition [202].”
- Authors
- Chen, D., Tang, P., Liu, L., Wang, F., Xing, H., Sun, L., & Jiang, Z.
- Affiliations
- First Affiliated Hospital of Zhengzhou University (CN)
- Department of Hematology, The first affiliated hospital of Zhengzhou University, Zhengzhou, 450052, China
- Corresponding author
- Jiang, Zhongxing
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2018-04-03
- Volume
- 17
- Issue
- 7
- Pages
- 858-867
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- PMC
- PMC6056211
- OpenAlex
- W2789518130
- Cited by
- 48
- References
- 9
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 1 · 2023: 3 · 2022: 5 · 2021: 15 · 2020: 9 · 2019: 5 · 2018: 2 · 2017: 1
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cell Cycle (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Hospital Foundation of the First Affiliated Hospital of Zhengzhou University
- National Youth Natural Science Foundation of China (81400108)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- bone marrow mesenchymal stem cells, multiple myeloma, PD-1/PD-L1 pathway, T cell suppression, CD4+ T cell proliferation, tumor microenvironment, Th1/Th2 balance, Th17/Treg imbalance, tumor growth, inflammation
- MeSH terms
- Animals, Bone Marrow Cells, Disease Models, Animal, Female, Lymphocyte Activation, Mice, Inbred C57BL, Multiple Myeloma, Signal Transduction, Gene Expression Regulation, Neoplastic, Survival Analysis, Cytokines, Th1 Cells, Th2 Cells, Coculture Techniques, RNA, Small Interfering, Mesenchymal Stem Cell Transplantation, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Th1-Th2 Balance, Th17 Cells, Mesenchymal Stem Cells, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review